Breaking News
August 17, 2018 - Bacterial activity in child’s mouth may serve as biomarkers for autism spectrum disorder
August 17, 2018 - Scripps Research scientists uncover new approach for treating thrombocytopenia
August 17, 2018 - Mathematical model shows the influence of human behavior on spread of infectious diseases
August 17, 2018 - Valley Hospital achieves Magnet recognition for fourth consecutive time
August 17, 2018 - Researchers describe link between poor oocyte development and oxidative stress in obese mice
August 17, 2018 - Hospitals battle for control over fast-growing heart-valve procedure
August 17, 2018 - AHA: Home-Delivered Meals Keep Heart Failure Patients Out of Hospital
August 17, 2018 - In Southern Mozambique, only half of people diagnosed with HIV enroll in medical care
August 17, 2018 - Researchers develop novel statistical method to evaluate gene-to-gene interactions linked with cancer
August 17, 2018 - Island Fertility joins Stony Brook Community Medical to provide comprehensive fertility care
August 17, 2018 - Study shows link between thinning of the retina and early sign of Parkinson’s disease
August 17, 2018 - Digital birth control app gets FDA nod
August 17, 2018 - FDA grants approval for first generic version of epinephrine auto-injector
August 17, 2018 - Federal advisory group publishes recommendations on prevention of acute, chronic pain
August 17, 2018 - 3D-printed human body parts to be used as teaching aids for surgical training
August 17, 2018 - U.S. murder, suicide rates climbing again
August 17, 2018 - This is your brain on… roller coasters?
August 17, 2018 - Report discusses whether all newborns should undergo genetic sequencing
August 17, 2018 - UCR receives 2018 Inspiring Programs in STEM Award from INSIGHT Into Diversity magazine
August 17, 2018 - Researchers publish new paper on developing vaccine candidates for Helminthic parasites
August 17, 2018 - Researchers develop new method to diagnose broad range of cancers using malaria protein
August 17, 2018 - Female mosquitoes quickly evolve selective mating behavior when faced with threats
August 17, 2018 - FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo’s FLT3 Inhibitor Quizartinib for Relapsed/Refractory FLT3-ITD AML
August 17, 2018 - Resistance training and exercise motivation go hand-in-hand
August 17, 2018 - A lesson for future doctors: Listen to and learn from your patients
August 17, 2018 - NUS study discovers a bidirectional regulator and shines light on A-to-I RNA editing in cancer cells
August 17, 2018 - Research shows link between high blood levels of omega-3s and better brain function in children
August 17, 2018 - Researchers propose new theory for how rare gene mutations cause Alzheimer’s disease
August 17, 2018 - New project to combat DMD-related fibrosis receives major funding boost
August 17, 2018 - Digital psychiatric therapy can ‘rewire’ the brain in children with ADHD, study shows
August 17, 2018 - Psychologist to assess how the brain maintains precise short-term and long-term memories
August 17, 2018 - Eating white button mushrooms could improve regulation of glucose in the liver
August 17, 2018 - Scientists identify mutational signatures in ovarian cancer
August 17, 2018 - Sun Pharma receives U.S. FDA approval for CEQUA to treat patients with dry eye disease
August 17, 2018 - Teva Announces Updated Indication and Vial Presentation for Granix (tbo-filgrastim) Injection in United States
August 17, 2018 - Study shows DNA methylation related to liver disease among obese patients
August 17, 2018 - Life on the border: Back at Stanford, ready to pitch in
August 17, 2018 - New device for accurately placing hemodialysis catheters on kidney patients
August 17, 2018 - New strategy accelerates, automates process of prototype molecule optimization
August 17, 2018 - Study finds role of autoimmunity in development of COPD
August 17, 2018 - Researchers transform research tool to study neuronal function
August 17, 2018 - Cognitive impairment does not equate to unhappiness in older adults
August 17, 2018 - Peer Comparisons Can Decrease Risky Prescribing Patterns
August 17, 2018 - Susceptible genes identified for childhood chronic kidney disease
August 17, 2018 - Research uncovers miscarriage cause, identifies potential targets for treatment
August 17, 2018 - Bacterial armor could be new target for antibiotics | News Center
August 17, 2018 - FDA expands approval of Vertex’ cystic fibrosis medicine to treat children aged 12 to
August 17, 2018 - Give Your Child a Head Start With Math
August 17, 2018 - Ground-breaking study tests whether rejected livers can be made viable for transplantation
August 16, 2018 - New algorithm could improve diagnosis of rare diseases | News Center
August 16, 2018 - SCHILLER introduces latest generation of ECG device, CARDIOVIT AT-102 G2
August 16, 2018 - Proper treatment, refraining from smoking can reduce heart disease risk from type 2 diabetes
August 16, 2018 - Mount Sinai study could transform treatment for patients with retinal degenerative diseases
August 16, 2018 - Penn researchers develop first mouse model of idiopathic pulmonary fibrosis
August 16, 2018 - Four tips to help prevent fall allergy symptoms
August 16, 2018 - Women’s Preventive Services Initiative says screen all women annually for urinary incontinence
August 16, 2018 - At Stanford, patient discovers the source of her headaches, nausea | News Center
August 16, 2018 - To Prevent Injuries in Young Baseball Players, Chris Ahmad Reaches Out to Parents
August 16, 2018 - Restoring blood flow may be linked to longer survival in patients with critical limb ischemia
August 16, 2018 - New model of genetically engineered immune cells may help fight solid tumors
August 16, 2018 - Maternal stress increases anxious and depressive-like behaviors in female offspring
August 16, 2018 - Childhood exposure to secondhand smoke increases risk of COPD death in adulthood
August 16, 2018 - Scientists uncover key control mechanism of DNA replication
August 16, 2018 - NIH begins first-in-human trial of experimental live, attenuated Zika virus vaccine
August 16, 2018 - Two diabetes medications don’t slow progression of type 2 diabetes in youth
August 16, 2018 - 5 Questions: How Stanford research is making MRI scans safer for kids | News Center
August 16, 2018 - Columbia Celebrates 25th Anniversary of White Coat Ceremony
August 16, 2018 - Phonak’s new smallest and most discreet Virto B-Titanium hearing aid
August 16, 2018 - New project aims to study growth of water-based microorganisms
August 16, 2018 - Immune cell found to play important role in photosensitivity
August 16, 2018 - Higher social dominance linked to faster decision-making in men
August 16, 2018 - Blood test in early pregnancy could determine a woman’s later risk for gestational diabetes
August 16, 2018 - New research confirms link between DDT exposure and autism
August 16, 2018 - Neurodevelopmental Anomalies, Birth Defects Linked to Zika ID’d
August 16, 2018 - Risk of heart failure up in ALVSD patients with diabetes
August 16, 2018 - Exercise reduces symptoms and fatigue in patients with chronic kidney disease
August 16, 2018 - Study reveals role of RUNX proteins in DNA repair
August 16, 2018 - New research finds no harm from average salt consumption
August 16, 2018 - Researchers develop new way of testing bacterial resistance to antibiotics
August 16, 2018 - Magnetic gene in aquarium fish could open doors to treatment for epilepsy, Parkinson’s
First Successful Gene Therapy for Hemophilia A

First Successful Gene Therapy for Hemophilia A

image_pdfDownload PDFimage_print

Action Points

  • This landmark study demonstrated the feasibility of gene transfer to normalize factor VIII levels in adults with hemophilia A.
  • Modest transaminase elevation was common, but self-limited.

ATLANTA — A single infusion of a gene therapy for hemophilia A led to normalization of factor VIII levels that persisted for a year, British investigators reported here.

Six of seven patients treated with the highest dose of the engineered therapy had factor VIII levels >50 IU/dL, and the seventh patient had therapeutic levels of factor VIII at 1 year. The high-dose cohort averaged 16 bleeding episodes a year before treatment and one episode afterward.

The most frequent adverse event was elevated serum alanine aminotransferase (ALT), reported K. John Pasi, MB ChB, PhD, of the Royal London Hospital, at the American Society of Hematology (ASH) meeting. The results were published simultaneously in the New England Journal of Medicine.

“Increases in factor VIII activity levels were dose dependent, with all seven participants in the high-dose cohort sustaining therapeutic levels at 1 year after gene transfer,” Pasi’s group noted in the published article. “In conjunction, the frequency of participant-treated bleeding episodes decreased markedly, with resultant cessation of factor VIII use. The absence of spontaneous bleeding in patients with severe hemophilia A factor VIII replacement therapy, regardless of the product half-life.”

The study is the first successful demonstration of gene therapy for hemophilia, as three previous trials with different genetically engineered products either failed to show a benefit, they added.

Combined with reported success for gene therapy for the less common hemophilia B, the results suggest that a cure for hemophilia may soon be within reach, according to the author of an accompanying editorial.

“These landmark studies … are leading the way to a cure for hemophilia,” wrote H. Marijke van den Berg, MD, PhD, of PedNet Hemophilia Research Foundation in Baarn, the Netherlands. “Prophylaxis with coagulation products could be discontinued in each study, and bleeding rates were reduced to zero, which is to be expected when factor VIII and factor IX levels are sustained at levels exceeding 5 IU per deciliter.”

If the initial results hold up in additional clinical evaluations, “children born with this devastating disease could benefit from a life without bleeding and other sequelae of the disease,” van den Berg added.

During an advance ASH media preview, Robert Brodsky, MD, of Johns Hopkins in Baltimore, included the gene therapy trial in a small group of abstracts that he characterized as “home run-type” studies. Like van den Berg, he said the impressive 52-week results suggest the engineered therapy offers a potential cure for hemophilia A.

The small clinical trial evaluated the safety and efficacy of a codon-optimized adeno-associated virus serotype 5 (AAV5) vector encoding a B-domain-deleted human factor VIII (AAV5). Until the successful results presented by Pasi’s group, the large size of the factor VIII coding region had posed a seemingly insurmountable obstacle improved outcomes in hemophilia A with gene therapy.

Preclinical evaluations of AAV5 (valoctocogene roxaparvovec) showed dose-dependent increases in factor VIII expression in mouse and nonhuman primate models of hemophilia A, providing a rationale for clinical evaluation. Investigators evaluated three doses of the gene therapy in a total of nine men with severe hemophilia A. Low and intermediate doses of the gene therapy (administered to one patient each) failed to achieve and maintain therapeutic levels of factor VIII.

Safety was the primary objective of the trial, and clinical efficacy was a secondary objective. The seven participants in the high-dose cohort and the patient who received the lowest dose of the gene therapy had increased ALT, which was asymptomatic and resolved without intervention or sequelae.

All seven patients in the high-dose cohort achieved therapeutic levels of factor VIII by week 16, the prespecified time point for efficacy assessment. The 5 IU/dL definition for therapeutic level is the cutoff between moderate and mild hemophilia.

“After week 20, the factor VIII activity level was consistently more than 50 IU per deciliter in six of seven participants, and in the remaining participant, the level typically ranged from 12 to 32 IU per deciliter,” the authors noted.

At week 52, the median factor VIII activity level for the high-dose cohort was 77 IU/dL.

In addition to the decline in bleeding episodes that accompanied the increase in factor VIII levels, the requirement for factor VIII also declined dramatically. The median annualized use of factor VIII decreased from 138 infusions per year pre-study to two infusions per year following gene therapy.

Analysis of biologic fluids and stool samples showed that residual vector DNA decreased over the course of the study period.

The authors pointed out that they did not assess the possibility of vector integration, and that the study protocol was not “designed to measure whether AAV5 infection was present in family members or close contacts.”

Pasi disclosed relevant relationships with Bayer HealthCare, Biotest, Novo Nordisk, Pfizer, Roche, SOBI, Octapharma, Shire, Alnylam, Biomarin, and Biogen Idec.

Van den Berg disclosed relevant relationshps with Bayer, CSL, NovoNordisk, Pfizer, Grifols, Sobi, and Bioverativ.

  • Reviewed by
    F. Perry Wilson, MD, MSCE Assistant Professor, Section of Nephrology, Yale School of Medicine and Dorothy Caputo, MA, BSN, RN, Nurse Planner

2017-12-09T09:04:50-0500

Tagged with:

About author

Related Articles